Loading publications…
The last 5 uploaded publications
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
Ana M. Aparicio, Andrew J. Armstrong, Diogo Assed Bastos, Gerhardt Attard, Karol Axcrona, Mouna Ayadi, Himisha Beltran, Anders Bjartell, Pierre Blanchard, María T. Bourlon, Alberto Briganti, Muhammad Bulbul, Consuelo Buttigliero, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N., Caroline S. Clarke, Noel W. Clarke, Johann S. de Bono, Maria De Santis, Ignacio Durán, Eleni Efstathiou, Onyeanunam Ngozi Ekeke, Tamer I H El Nahas, Louise Emmett, Stefano Fanti, Omolara Fatiregun, Felix Y. Feng, Peter C.C. Fong, Valérie Fonteyne, Nicola Fossati, Daniel J. George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Michael S. Hofman, Thomas A. Hope, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Anthony M. Joshua, R. Kanesvaran, Daniel Keizman, Raja B. Khauli, Gero Kramer, Stacy Loeb, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Mika Matikainen, Ray McDermott, Rana R. McKay, Niven Mehra, Axel S. Merseburger, Alicia K. Morgans, Michael J. Morris, Hind Mrabti, Deborah Mukherji, Silke Gillessen, Fabio Turco, Ian D. Davis, Jason A. Efstathiou, Karim Fizazi, Nicholas D. James, Neal D. Shore, Eric J. Small, Matthew R. Smith, Christopher J. Sweeney, Bertrand Tombal, Thomas Zilli, Neeraj Agarwal, Emmanuel S. Antonarakis, Declan G. Murphy, Vedang Murthy, Shingai B.A. Mutambirwa, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Chris Parker, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Raphaële Renard‐Penna, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Shahneen Sandhu, Oliver A. Sartor, Edward M. Schaeffer, Howard I. Scher (2024). Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). , DOI: https://doi.org/10.1016/j.eururo.2024.09.017.
Article62 days agoNiraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
Matthew R. Smith, Howard I. Scher, Shahneen Sandhu, Eleni Efstathiou, Primo N. Lara, Evan Y. Yu, Daniel J. George, Kim N., Fred Saad, Olof Ståhl, David Olmos, Daniel C. Danila, Gary Mason, Byron M. Espina, Xin Zhao, Karen A. Urtishak, Peter Francis, Angela Lopez‐Gitlitz, Karim Fizazi, Francis Parnis, Anthony M. Joshua, Lisa G. Horvath, Christopher Steer, Gavin Marx, Shahneen Sandhu, Howard Gurney, T. J. Ferguson, Siska Van Bruwaene, Daisy Luyten, Peter Schatteman, Nicolaas Lumen, Luc Dirix, Jean‐Charles Goeminne, Thierry Gil, Emmanuel Seront, Christof Vulsteke, Celio Kussumoto, Fábio Franke, Fabrício Augusto Martinelli de Oliveira, Andrea Juliana Gomes, Hélio Pinczowski, Daniel D’Almeida Preto, Luis Eduardo Rosa Zucca, Giuliano Santos Borges, André M. Murad, Fred Saad, Kim N., Yves Fradet, Neil Fleshner, Urban Emmenegger, Klaus Brasso, Karim Fizazi, Stéphane Culine, Antoine Thiery-Vuillemin, Florence Joly, Aude Fléchon, Werner Hilgers, Jean‐Christophe Eymard, Delphine Borchiellini, Philippe Barthélémy, Raanan Berger, Raya Leibowitz‐Amit, Wilmosh Mermershtain, Keren Rouvinov, Avivit Peer, Svetlana Kovel, Avishay Sella, Martijn P. Lolkema, Alfonsus Johannes Maria van den Eertwegh, Johannes Voortman, Maureen J.B. Aarts, Jourik A. Gietema, Choung‐Soo Kim, Young Deuk Choi, Byung Ha Chung, Rustem Gafanov, Evgeniy Kopyltsov, Evgeny A. Usynin, Joan Carles, Begoña Mellado, Pablo Maroto, Jesús García-Donás, Juan F. Rodríguez-Moreno, Ignacio Durán, Begoña Pérez-Valderrama, Elena Castro, David Olmos, María José Méndez-Vidal, D. Lorente Estellés, Regina Gironés Sarrió, José Muñoz-Langa, Urbano Anido Herranz, Javier Puente, E.A. Castellanos Abella, Martin Hellström, Anders Widmark, Ingela Franck Lissbrant, Åsa Jellvert, Cecilia Külich, René Blom (2022). Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. , 23(3), DOI: https://doi.org/10.1016/s1470-2045(21)00757-9.
Article62 days agoNiraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
Evan Y. Yu, Daniel J. George, Kim N., Fred Saad, Olof Ståhl, David Olmos, Daniel C. Danila, Gary Mason, Byron M. Espina, Xin Zhao, Karen A. Urtishak, Peter Francis, Angela Lopez‐Gitlitz, Karim Fizazi, Francis Parnis, Anthony M. Joshua, Lisa G. Horvath, Christopher Steer, Gavin Marx, Shahneen Sandhu, Howard Gurney, T. J. Ferguson, Siska Van Bruwaene, Daisy Luyten, Peter Schatteman, Nicolaas Lumen, Luc Dirix, Jean‐Charles Goeminne, Thierry Gil, Emmanuel Seront, Christof Vulsteke, Celio Kussumoto, Fábio Franke, Fabrício Augusto Martinelli de Oliveira, Andrea Juliana Gomes, Hélio Pinczowski, Daniel D’Almeida Preto, Luis Eduardo Rosa Zucca, Giuliano Santos Borges, André M. Murad, Fred Saad, Kim N., Yves Fradet, Neil Fleshner, Urban Emmenegger, Klaus Brasso, Karim Fizazi, Stéphane Culine, Antoine Thiery-Vuillemin, Florence Joly, Aude Fléchon, Werner Hilgers, Jean‐Christophe Eymard, Delphine Borchiellini, Philippe Barthélémy, Raanan Berger, Raya Leibowitz‐Amit, Wilmosh Mermershtain, Keren Rouvinov, Avivit Peer, Svetlana Kovel, Avishay Sella, Martijn P. Lolkema, Alfonsus Johannes Maria van den Eertwegh, Johannes Voortman, Maureen J.B. Aarts, Jourik A. Gietema, Choung‐Soo Kim, Young Deuk Choi, Byung Ha Chung, Rustem Gafanov, Evgeniy Kopyltsov, Evgeny A. Usynin, Joan Carles, Begoña Mellado, Pablo Maroto, Jesús García-Donás, Juan F. Rodríguez-Moreno, Ignacio Durán, Begoña Pérez-Valderrama, Elena Castro, David Olmos, María José Méndez-Vidal, D. Lorente Estellés, Regina Gironés Sarrió, José Muñoz-Langa, Urbano Anido Herranz, Javier Puente, E.A. Castellanos Abella, Martin Hellström, Anders Widmark, Ingela Franck Lissbrant, Åsa Jellvert, Cecilia Külich, René Blom, Matthew R. Smith, Howard I. Scher, Shahneen Sandhu, Eleni Efstathiou, Primo N. Lara (2022). Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. , 23(3), DOI: https://doi.org/10.1016/s1470-2045(21)00757-9.
Article62 days ago582P Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD)
Matthew R. Smith, Shahneen Sandhu, Daniel J. George, K.N. Chi, Fred Saad, Antoine Thiery-Vuillemin, O. Ståhl, David Olmos, Daniel C. Danila, Rustem Gafanov, Elena Castro, Helen Moon, Anthony M. Joshua, Gary Mason, Byron M. Espina, Y. Liu, Katherine B. Bevans, Angela Lopez‐Gitlitz, Peter Francis, Karim Fizazi (2021). 582P Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD). , 32, DOI: https://doi.org/10.1016/j.annonc.2021.08.1095.
Article62 days agoNiraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study.
Matthew R. Smith, Karim Fizazi, Shahneen Sandhu, William Kevin Kelly, Eleni Efstathiou, Primo N. Lara, Evan Y. Yu, Daniel J. George, Kim N., Fred Saad, Jason M. Summa, Jamie Freedman, Gary Mason, Byron M. Espina, Eugene Zhu, Deborah Ricci, Linda A. Snyder, Jason S. Simon, Shinta Cheng, Howard I. Scher (2020). Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study.. , 38(6_suppl), DOI: https://doi.org/10.1200/jco.2020.38.6_suppl.118.
Article62 days ago